Wiley Bros. Aintree Capital, LLC Virios Therapeutics, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Virios Therapeutics, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 11,000 shares of VIRI stock, worth $48,840. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 11,000
-0.0%
Holding current value
$48,840
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VIRI
# of Institutions
28Shares Held
1.12MCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA231KShares$1.02 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA209KShares$927,4400.0% of portfolio
-
Ubs Group Ag186KShares$826,1150.0% of portfolio
-
Hrt Financial LP New York, NY81.6KShares$362,1880.0% of portfolio
-
Two Sigma Securities, LLC New York, NY53.4KShares$237,0600.0% of portfolio
About Virios Therapeutics, Inc.
- Ticker VIRI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,330,400
- Market Cap $81.4M
- Description
- Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...